Trials / Unknown
UnknownNCT02614846
Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hetrombopag Olamine |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-03-01
- First posted
- 2015-11-25
- Last updated
- 2015-11-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02614846. Inclusion in this directory is not an endorsement.